Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistanceDiana Zatreanu, Christopher J. Lord, Martin E. Swarbrick et al.|Nature Communications|2021Cited by 358
Abstract P056: Polθ inhibitors elicit <i>BRCA</i>-gene synthetic lethality and target PARP inhibitor resistanceDiana Zatreanu, Christopher J. Lord, Helen M.R. Robinson et al.|Molecular Cancer Therapeutics|2021Cited by 3
Abstract CT267: First results of ART0380 (an ATR kinase inhibitor) with low dose irinotecan in advanced or metastatic solid tumorsSusanna V. Ulahannan, Babar Bashir, Jason T. Henry et al.|Cancer Research|2025Cited by 3
Abstract 5697: Targeting PARP inhibitor resistance with Polθ inhibitorsDiana Zatreanu, Christopher J. Lord, Helen M. Robinson et al.|Cancer Research|2022Cited by 1